These promising data in morbidly obese patients reinforce the potential of EndoBarrier as an innovative, non-surgical therapeutic for patients battling obesity and type 2 diabetes, said Stuart A. Randle, chief executive officer of GI Dynamics. This was the first European clinical weight loss study conducted with the EndoBarrier, and since then the EndoBarrier has been successfully implanted in more than 250 patients. As GI Dynamics has expanded the clinical development program for EndoBarrier in patients with obesity and type 2 diabetes, we have continued to see impressive results, and have been able to continuously refine our device and improve the implantation procedure.

GI Dynamics is defining a new class of metabolic treatment options that fit between pharmaceutical regimens and surgery, called non-surgical therapeutics. Non-surgical therapeutics are designed to eliminate or reduce the risks and side effects associated with pharmaceutical regimens as well as surgical options. This new class of treatment can be performed easily and quickly without any incisions, thus reducing patient anxiety and recuperative time. Unlike traditional pharmaceutical approaches, non-surgical therapeutics remove the burden of dose regimen compliance from the patient. Additionally, non-surgical therapeutics hold the potential to improve the patient ™s overall health, by providing the control necessary to institute lifestyle and nutritional improvements to maintain therapeutic effect, while being easily removed once the desired effect has been attained and lifestyle changes implemented.

SOURCE GI Dynamics